Seif Haddaoui , Yosra Berrazega , Nesrine Mejri , Myriam Saadi , Ahmed Anas Haouari , Alia Zehani , Haifa Rachdi
{"title":"Durable disease control with cabozantinib in metastatic chromophobe renal cell carcinoma: A rare case with promising outcomes","authors":"Seif Haddaoui , Yosra Berrazega , Nesrine Mejri , Myriam Saadi , Ahmed Anas Haouari , Alia Zehani , Haifa Rachdi","doi":"10.1016/j.eucr.2025.103017","DOIUrl":null,"url":null,"abstract":"<div><div>Chromophobe renal cell carcinoma (chRCC) is a rare RCC subtype with limited treatment data. Cabozantinib, a multikinase inhibitor, is effective in clear cell RCC but lacks robust evidence in chRCC.</div><div>A 26-year-old male with metastatic chRCC achieved prolonged disease control on cabozantinib despite treatment interruptions. After first-line pazopanib failure, cabozantinib was initiated in January 2023, maintaining stable disease for over two years with only grade I toxicities.</div><div>Cabozantinib appears effective in metastatic chRCC, offering prolonged stability with manageable toxicity. Further research is needed to establish its role in this rare RCC subtype.</div></div>","PeriodicalId":38188,"journal":{"name":"Urology Case Reports","volume":"60 ","pages":"Article 103017"},"PeriodicalIF":0.4000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214442025000889","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Chromophobe renal cell carcinoma (chRCC) is a rare RCC subtype with limited treatment data. Cabozantinib, a multikinase inhibitor, is effective in clear cell RCC but lacks robust evidence in chRCC.
A 26-year-old male with metastatic chRCC achieved prolonged disease control on cabozantinib despite treatment interruptions. After first-line pazopanib failure, cabozantinib was initiated in January 2023, maintaining stable disease for over two years with only grade I toxicities.
Cabozantinib appears effective in metastatic chRCC, offering prolonged stability with manageable toxicity. Further research is needed to establish its role in this rare RCC subtype.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
